127 , 128 A phase 1 study of a single intra-articular dose of SM04690 in 61 participants with moderate osteoarthritis showed acceptable safety, with exploratory clinical endpoints that showed a positive trend towards improvement in pain and joint space narrowing. 129 A phase 2 study of 455 individuals with unilateral knee osteoarthritis, although not reaching its primary endpoint (improvement of WOMAC pain at week 13), showed improvement in pain and an increase in joint space indicative of disease modification, which was especially evident in people with unilateral disease. 130 In May 2019, the phase 3 studies were launched (registered on ClinicalTrials.gov , NCT04385303 ).
← all excerpts
Of mice and men: converging on a common molecular understanding of osteoarthritis.
1
—
—